AcelRx Pharmaceuticals Inc (ACRX)

2.60
NASDAQ : Health Care
Prev Close 2.60
Day Low/High 2.60 / 2.65
52 Wk Low/High 2.40 / 4.08
Avg Volume 204.50K
Exchange NASDAQ
Shares Outstanding 45.34M
Market Cap 117.88M
EPS -0.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

AcelRx Pharmaceuticals Appoints Vincent J. Angotti Chief Executive Officer

AcelRx Pharmaceuticals Appoints Vincent J. Angotti Chief Executive Officer

- Howie Rosen to Continue on Board of Directors -

AcelRx Pharmaceuticals Reports On ARX-04 Market And Landscape Presented At Analyst & Investor Event

AcelRx Pharmaceuticals Reports On ARX-04 Market And Landscape Presented At Analyst & Investor Event

- Peak revenue opportunity for ARX-04 estimated to be $1.1 billion

AcelRx Pharmaceuticals To Host Analyst & Investor Event On December 1, 2016

AcelRx Pharmaceuticals To Host Analyst & Investor Event On December 1, 2016

- Expert panel to discuss market opportunity in emergency medicine for investigational agent ARX-04 (sufentanil sublingual tablet, 30 mcg) for the treatment of moderate-to-severe acute pain

ACRX: Insiders vs. Shorts

ACRX: Insiders vs. Shorts

The most recent short interest data was recently released for the 09/30/2016 settlement date, and AcelRx Pharmaceuticals Inc is one of the most shorted stocks of the Russell 3000, based on 8.72 "days to cover" versus the median component at 5.36. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Here's Why AcelRx Pharmaceuticals (ACRX) Stock Gained Today

Here's Why AcelRx Pharmaceuticals (ACRX) Stock Gained Today

AcelRx Pharmaceuticals (ACRX) announced on Thursday that ARX-04, its experimental pain relief drug, had positive results in a phase III clinical trial.

AcelRx Pharmaceuticals To Announce Topline Results In Phase 3 Study Of ARX-04 In Patients With Post-Operative Moderate-to-Severe Acute Pain

AcelRx Pharmaceuticals To Announce Topline Results In Phase 3 Study Of ARX-04 In Patients With Post-Operative Moderate-to-Severe Acute Pain

Management to host conference call tomorrow at 9:00 a.m. ET (6:00 a.m. PT) Thursday, September 15th

AcelRx Pharmaceuticals' ARX-04 Phase 3 Trial Met Its Primary Endpoint, Reduced Pain Intensity In ER Patients With Moderate-to-Severe Acute Pain

AcelRx Pharmaceuticals' ARX-04 Phase 3 Trial Met Its Primary Endpoint, Reduced Pain Intensity In ER Patients With Moderate-to-Severe Acute Pain

- Topline SAP302 Results Presented at Military Health System Research Symposium -